Synbody Mediator for MRSA Sensitization to Beta-Lactams
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for methicillin-resistant Staphylococcus aureus (MRSA) infections are limited, with few new antibiotic molecules in development and existing antibiotics often ineffective due to bacterial resistance.
Innovation Solution
Development of a synbody with direct antibiotic activity against MRSA, capable of targeting the cell membrane and used in conjunction with beta-lactam antibiotics to enhance treatment efficacy, represented by specific peptide formulas and compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional beta-lactam antibiotics are used to treat MRSA infections, then treatment efficacy is poor due to bacterial resistance, but developing new antibiotic molecules is difficult with few new molecules nearing approval
Solution Approach 1:
The patent employs synbodies as intermediary molecules that sensitize MRSA to beta-lactam antibiotics. These synbodies act as mediators between the antibiotic and the bacterial cell membrane, facilitating antibiotic penetration and enhancing killing efficacy without requiring development of entirely new antibiotic molecules
Solution Approach 2:
The invention creates composite therapeutic formulations combining synbodies with conventional beta-lactam antibiotics. This composite approach merges the membrane-targeting capability of synbodies with the cell-wall synthesis inhibition of beta-lactams, achieving synergistic effects that overcome MRSA resistance
2Reliability
If antimicrobial peptides are developed as new antibiotics, then antibacterial activity is achieved, but in vivo behavior is often poor
Solution Approach 1:
The synbodies designed in this patent exhibit multi-functionality: they directly target and disrupt the bacterial cell membrane, facilitate antibiotic penetration, and enhance bacterial killing. This universal mechanism of action improves in vivo efficacy compared to conventional AMPs while maintaining potent antibacterial activity
3Adaptability or versatility
If agents are developed to sensitize MRSA to beta-lactam antibiotics, then treatment options are expanded, but few such agents are currently available
Solution Approach 1:
The patent modifies the structural parameters of peptide molecules to create synbodies with optimized properties. By adjusting peptide sequence, length, and structural features, the invention enhances membrane targeting and antibiotic sensitization capabilities, expanding treatment options with improved agents
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The synbody demonstrates bactericidal activity against multiple MRSA strains and synergistic effects with beta-lactam antibiotics, effectively reducing bacterial growth and infection severity in both in vitro and in vivo models.
Implementation Method 1
The synbody is bactericidal against multiple strains of MRSA and likely targets the cell membrane
Implementation Method 2
The synbody also can be used in conjugation with currently approved β-lactam antibiotics, such as oxacillin, to treat MRSA infections
Data Source
AI summary
Provided herein are compounds and compositions having antibiotic activity against methicillin resistant Staphylococcus aureus (MRSA). In particular, provided herein is a synbody that bactericidal against multiple strains of MRSA and that can be used in conjugation with currently approved β-lactam antibiotics to treat MRSA strains having resistance to β-lactam treatment. Also provided are methods of using the compounds and compositions for treating, preventing or reducing MRSA infections.